Proteasome inhibitors

• US 8,530,694 B2
• Filed: 08/15/2011
• Issued: 09/10/2013
• Est. Priority Date: 08/06/2007
• Status: Active Grant

• Current Assignee: Takeda Pharmaceutical Company Limited
• Original Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Inventors: Olhava, Edward J., Danca, Mihaela Diana
• Primary Examiner(s): WITHERSPOON, SIKARL A
• Application Number:
  US13/209,511
• Publication Number:
  US 20110301124A1
• Time in Patent Office: 757 Days
• Field of Search: 562/7, 562/450, 564/8, 564/169, 514/64
• US Class Current: 562/7
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/454 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 31/69 Boron compounds
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07C 233/83 of an acyclic saturated carbon skeleton
• CPC Class Codes: C07F 5/025 Boronic and borinic acid compounds
• CPC Class Codes: C07F 5/05 Cyclic compounds having at least one ring containing boron but no carbon in the ring

Abstract

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Claims

1. A compound of formula (I):

2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. A method of treating cancer, comprising treating a patient in need of such treatment with a compound according to claim 1.

4. A method of treating cancer, comprising treating a patient in need of such treatment with a pharmaceutical composition according to claim 2.